Eribulin
Tubulin Inhibitor
DB08871
Approved Indication
For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
2
Targets
0
Resistance Mutations
4
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Eribulin inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into nonproductive aggregates. Eribulin exerts its effects via a tubulin-based antimitotic mechanism leading to G2/M cell-cycle block, disruption of mitotic spindles, and, ultimately, apoptotic cell death after prolonged mitotic blockage. [FDA]
Details
DrugBank ID
DB08871 ↗
Approval Date
2010-11-15
Molecular Weight
729.8966 g/mol
Drug Class
Tubulin Inhibitor
ATC Codes
L01XX41
Synonyms
—
PubChem
CID: 73425383 ↗
ChEMBL
CHEMBL1683590 ↗
SMILES
[H][C@@]12O[C@@]3([H])CCC4CC(=O)C[C@H]5[C@H](C[C@H]6O[C@H](C[C@@H](C)C6=C)CC[C@@H]6O[C@H](CC6=C)CC[C@@]67C[C@@H](O[C@H]1[C@@H](O6)[C@@]3([H])O4)[C@@H]2O7)O[C@H](C[C@H](O)CN)[C@@H]5OC
ADMET Profile
Computing properties…
Drug References (DrugBank)